MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced that Stefan Weber, CEO, will present at the Jefferies 2017 Healthcare Conference in New York, NY on Wednesday, June 7, 2016 at 9:00 a.m. ET.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central nervous system (CNS) and pain.
The Company is headquartered in Bresso near Milan, Italy, with a
subsidiary in Morristown, NJ, USA. Xadago® (safinamide) has received
marketing authorization for the treatment of Parkinson’s disease in the
European Union, Switzerland and the USA, and is commercialized by
Newron’s partner Zambon. US WorldMeds holds the commercialization rights
in the USA. In addition to Xadago® for Parkinson’s disease, Newron has a
strong pipeline of promising treatments for rare disease patients at
various stages of clinical development, including sarizotan for patients
with Rett syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing Evenamide as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia. http://www.newron.com/en.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005050/en/
